SmartInhaler

Adherium receives additional FDA clearance for OTC sale of inhaler sensors in the US

Credit: Adherium on

By Dave Muoio July 27, 2018
Connected inhaler sensor maker Adherium has received 510(k) clearance for US over-the-counter sales of its Hailie sensor, formerly known as Smartinhaler. Specifically, individual versions of the device have been cleared for use with the asthma inhalers ProAir HFA, Ventolin HFA, and Flovent HFA. “This latest clearance kicks off our official entry into the US consumer market, giving the tens of...
By Jonah Comstock January 24, 2018
New Zealand-based smart inhaler company Adherium, which up until now has distributed its products via pharma sales channels in Europe and Australia, plans to expand into the United States in the first half of 2018 with a direct-to-consumer (and direct-to-payer) strategy. “We’ve had a great relationship over the last couple of years with AstraZeneca, we’ve launched in a couple dozen countries now...
By Heather Mack December 12, 2016
Melbourne, Australia-based smart inhaler company Adherium has been selected to supply the technology for a multi-country research program in Europe that will seek to establish whether home monitoring and mobile health tools can be used to manage asthma. Adherium’s Smartinhaler technology, which uses sensors to track when medication is taken and then sends the data via Bluetooth to mobile devices...
By Jonah Comstock November 17, 2016
Correction: A previous version of this article misstated the adherence figure.  Adherium’s Smartinhaler has been shown to increase medication adherence by 43 percent and reduce hospitalization by a factor of five, according to a new study conducted at Sheffield Children’s Hospital in the UK and published in the journal Thorax. The randomized control trial included 77 children with asthma. “This...
By Jonah Comstock September 30, 2015
Adherium, the Australian connected inhaler company that partnered with AstraZeneca earlier this summer, has released data from three small studies of the company's Smartinhaler system. Data from the studies, all of which involved children and adolescents, indicate a 144 percent increase in adherence for patients using the connected devices, a 14.9 percent increase in lung function and a 37...
By Jonah Comstock August 19, 2015
Adherium Limited, a New Zealand company working on a smart inhaler, has raised $25.6 million ($35 million AU) in an initial public offering on the Australian Securities Exchange, including a $3 million investment from its partner pharma company AstraZeneca, which just last month announced a longterm commercialization agreement with the company. Adherium makes a line of medical devices that...
By Brian Dolan June 2, 2014
New Zealand-based medical device company Nexus6 has received FDA clearance for its smartphone-connected inhaler, SmartTouch, as a class II medical device. The new SmartTouch device has been cleared as a prescribable Metered Dose Inhaler (MDI) with a handful of intended uses: in clinical trials; in clinical practice, and for patient self-management. In all cases the device is used to help track...